The Purple Sky Store
Men's Heavy Blend Zip Hoodie (Embroidered Purple Ribbon)
Men's Heavy Blend Zip Hoodie (Embroidered Purple Ribbon)
Couldn't load pickup availability
Beyond comfort, this hoodie supports a cause. 40% of all revenue from the Unity Fleece Zip Hoodie goes to Sky Foundation, a non-profit that funds pancreatic cancer research, allowing each purchase to contribute to making a difference.
Soft fleece fabric (8 oz/yd² or 271 g/m²) for warmth and comfort
50% cotton, 50% polyester blend, with air-jet spun yarn to reduce pilling
Regular fit with durable metal zipper and front pouch pockets
Unlined hood with color-matched drawcord
Double-needle stitching at shoulders, armholes, neck, waistband, and cuffs
Safety Green color option compliant with ANSI/ISEA 107
Share



















Recent News
View all-
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
-
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
-
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...